一个新的简单慢性心力衰竭预后指数,基于五个一般参数
Helena Hipólito-Reis1, Carolina Guimarães1, Catarina Elias1
1Internal Medicine Department, Centro Hospitalar e Universitário São João, Portugal.
International journal of cardiology
|January 26, 2025
概括
一个新的指数将B型尿素 (BNP) 与年龄,,血红蛋白和功能相结合,改善了心力衰竭 (HF) 死亡率预测. 患有高BASIC指数得分的患者面临近三倍的死亡风险.
科学领域:
- 心脏病学 心脏病学
- 临床医学 临床医学
- 生物标志物研究 生物标志物研究
背景情况:
- 心力衰竭 (HF) 的预后预测是复杂的,没有任何单个标志物被证明是始终有效的.
- 现有的方法往往缺乏对患者结果的全面预测能力.
研究的目的:
- 使用现有临床参数,开发和验证一种新的心力衰竭 (HF) 预后指数.
- 评估这个新指数,即BASIC指数,与单独的B型尿素 (BNP) 相比,是否改善了风险分层.
主要方法:
- 对1065名患有慢性心功能障碍的心力衰竭的成人门诊患者的回顾性分析.
- 基本指数的计算: (BNP * 年龄 ^ 2) / (血清 * 血红蛋白 * eGFR).
- 评估指数与所有原因死亡率的关联,使用接收器运营商特征 (ROC) 曲线和考克斯回归分析.
主要成果:
- 与BNP单独 (AUC 0.69) 相比,BASIC指数在预测全因死亡率方面表现出更高的预后性能 (AUC 0.73).
- 一个9.3的BASIC指数切断线确定了患有明显更高死亡风险的患者.
- 患者的BASIC指数>9.3具有多变量调整的危险比为2.70所有原因的死亡率.
结论:
- 基本指数,包括BNP,年龄,血清,血红蛋白和估计的膜过率 (eGFR),显著提高了心力衰竭的预后预测.
- 超过9.3的BASIC指数识别了近3倍死亡风险增加的患者,为风险分层提供了有价值的工具.
相关概念视频
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:26Imbalances in Cardiac Output
1.3K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.3K
01:22Heart Failure Drugs: β-Blockers
311
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
311
01:26Heart Failure Drugs: Inotropic Agents
507
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
507
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
375
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
375